Article
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
PloS one - 1 Jan 2015
Kovari Helen, Russmann Stefan, Ledergerber Bruno, Müller Daniel, Rotger Margalida, Velli Pablo, Cavassini Matthias, Ambrosioni Juan, Bregenzer Andrea, Stöckle Marcel, Bernasconi Enos, Rauch Andri, Speck Roberto F
Abstract excerpt
BACKGROUND: Ribavirin (RBV) is an essential component of most current hepatitis C (HCV) treatment regimens and still standard of care in the combination with pegylated interferon (pegIFN) to treat chronic HCV in resource limited settings. Study results in HIV/HCV-coinfected patients are contradic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.